PARTNERS

Addressing the human health impacts of AMR will require building a strong and motivated coalition of like-minded health officials, clinicians, laboratorians, policymakers, patients and leaders.

IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

BBC is a joint initiative of Department of Biotechnology, Government of India and Department of Electronics, IT, BT and S&T, Government of Karnataka. BBC is a State-of-the-art translational research and entrepreneurship centre catering to all the needs of start-ups in life science.

BD is one of the largest global medical technology companies in the world and is advancing the world of health^TM by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers.

IHMA supports companies needing:

• Pre-clinical studies for regulatory filings
• Global laboratory services for all phases of clinical trials
• Antimicrobial resistance (AMR) surveillance (bacterial and fungal)
• Molecular characterization and detection of infectious agents
• New therapeutic approaches (bacteriophage, vaccine, etc.)
• In vitro diagnostic device studies

Molzym is committed to the development of innovative solutions to serve biological research and diagnosis of infectious diseases. Its developmental efforts are focused on new processes enabling and facilitating the molecular diagnosis of infectious diseases caused by bacteria and fungi.

BSI is protecting the efficacy of antibiotics for future generations with the BSI Kitemark™ for minimized risk of antimicrobial resistance certification programme.

Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculosis mycobacteria, malaria, dengue, leishmania, bacterial infections, COVID-19 and RSV, spanning over early-stage discovery to late-stage clinical trials.